Annexon, Inc. (NASDAQ:ANNX) Shares Acquired by Ameriprise Financial Inc.

Ameriprise Financial Inc. grew its stake in shares of Annexon, Inc. (NASDAQ:ANNX - Free Report) by 483.6% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 926,642 shares of the company's stock after acquiring an additional 767,869 shares during the quarter. Ameriprise Financial Inc. owned about 0.87% of Annexon worth $4,754,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Vanguard Group Inc. grew its holdings in shares of Annexon by 11.6% during the 4th quarter. Vanguard Group Inc. now owns 5,546,918 shares of the company's stock worth $28,456,000 after purchasing an additional 576,625 shares during the period. Candriam S.C.A. grew its holdings in shares of Annexon by 15.6% during the 4th quarter. Candriam S.C.A. now owns 2,534,230 shares of the company's stock worth $13,001,000 after purchasing an additional 341,431 shares during the period. Geode Capital Management LLC grew its holdings in shares of Annexon by 1.3% during the 4th quarter. Geode Capital Management LLC now owns 2,171,478 shares of the company's stock worth $11,142,000 after purchasing an additional 27,843 shares during the period. Dimensional Fund Advisors LP grew its holdings in shares of Annexon by 20.5% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,360,076 shares of the company's stock worth $6,977,000 after purchasing an additional 231,034 shares during the period. Finally, Price T Rowe Associates Inc. MD grew its holdings in shares of Annexon by 6.7% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,104,385 shares of the company's stock worth $5,667,000 after purchasing an additional 69,733 shares during the period.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on ANNX. HC Wainwright decreased their target price on Annexon from $20.00 to $14.00 and set a "buy" rating for the company in a report on Wednesday, May 14th. Needham & Company LLC decreased their price target on Annexon from $16.00 to $11.00 and set a "buy" rating for the company in a report on Tuesday, May 13th.

Annexon Price Performance

NASDAQ ANNX traded up $0.09 on Wednesday, reaching $2.06. The company had a trading volume of 645,196 shares, compared to its average volume of 1,781,957. The firm has a market capitalization of $225.46 million, a PE ratio of -1.97 and a beta of 1.24. Annexon, Inc. has a 1 year low of $1.29 and a 1 year high of $7.85. The firm has a 50-day moving average of $1.84 and a 200-day moving average of $3.40.

Annexon (NASDAQ:ANNX - Get Free Report) last released its quarterly earnings results on Monday, May 12th. The company reported ($0.37) earnings per share for the quarter, missing analysts' consensus estimates of ($0.30) by ($0.07). As a group, sell-side analysts expect that Annexon, Inc. will post -0.96 EPS for the current fiscal year.

Annexon Company Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.